EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Y-90 anti-CD20 monoclonal antibody dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkins lymphoma



Y-90 anti-CD20 monoclonal antibody dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkins lymphoma



Journal of Nuclear Medicine 38(5 SUPPL ): 251P




(PDF emailed within 1 workday: $29.90)

Accession: 034256879

Download citation: RISBibTeXText



Related references

IDEC-Y2B8 dosimetry calculated from 111In anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkins lymphoma emphasis on bone marrow. Blood 90(10 SUPPL 1 PART 1): 510A, Nov 15, 1997

The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkins lymphoma cell lines. Blood 88(10 SUPPL 1 PART 1-2): 637A, 1996

Multicenter randomized phase II study of the monoclonal anti-CD20 antibody Rituximab in patients with intermediate/high grade non-Hodgkins lymphoma. Annals of Hematology 77(SUPPL 2): S180, 1998

Monoclonal anti-CD20 antibody rituximab is safe and efficient in patients with CD20-positive Hodgkins lymphoma. Onkologie 23(Sonderheft 7): 147, October, 2000

The monoclonal antibody anti-CD20 for the treatment of patients with low grade non Hodgkins lymphoma. Annals of Hematology 77(SUPPL 2): S26, 1998

Monoclonal anti-CD20 antibody rituximab for treatment of CD20-positive Hodgkins lymphoma The German experience. Blood 96(11 Part 1): 729a, November 16, 2000

Human-mouse chimeric 131I-labeled anti-CD20 monoclonal antibody in relapsed non-Hodgkins lymphoma Dosimetry and radioimmunotherapy. Journal of Nuclear Medicine 41(5 Suppl ): 268P, 2000

A phase II study of fludarabine phosphate and mitoxantrone followed by anti-CD20 monoclonal antibody in the treatment of patients with newly diagnosed, advanced low-grade non-Hodgkins lymphoma Interim results. Blood 102(11): 412a, November 16, 2003

CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy. Journal of the American Academy of Dermatology 46(3): 441-443, 2002

Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Japanese Journal Of Cancer Research. 89(7): 748-756, Y, 1998

Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma. Chinese Journal of Cancer Research 28(2): 197-208, 2016

Treatment of patients with mantle-cell and aggressive B-cell non-Hodgkins lymphoma using the monoclonal anti-CD20 antibody rituximab Evaluation of safety and response. Blood 94(10 SUPPL 1 PART 2): 270b, Nov 15, 1999

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. Journal of Clinical Oncology 17(1): 268-276, 1999

Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice. Bmc Cancer 5(): 103-103, 2005

Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy. Japanese Journal of Clinical Hematology 45(10): 1129-1134, 2004